Literature DB >> 17033776

[Rational minimally invasive treatment of pAOD: when should a conservative approach, PTA, or stent be chosen?].

S Müller-Hülsbeck1.   

Abstract

In order to obtain optimal results and satisfied patients, rational therapy of pAOD should strictly follow national and international society guidelines. In particular cases an individual therapeutic concept seems justified beyond these guidelines. Based on clinical data and driven by costs, aortic and iliac lesions may be treated by PTA or selective stent placement with equal results; however, long-term data justify also primary, direct stenting. For treatment of infrainguinal and popliteal stenotic lesions primary stenting should be restricted to PTA failure (dissection, recoil, occlusion); except for treatment of extended lesions, primary stenting compared to PTA alone seems beneficial in terms of midterm patency. Endovascular procedures below the knee and at the toe should be limited to existing limb-threatening ischemia in order to save the extremity; whether PTA or stenting is advantageous has not yet determined.

Entities:  

Mesh:

Year:  2006        PMID: 17033776     DOI: 10.1007/s00117-006-1430-3

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  29 in total

1.  Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions.

Authors:  J Grimm; S Müller-Hülsbeck; T Jahnke; C Hilbert; J Brossmann; M Heller
Journal:  J Vasc Interv Radiol       Date:  2001-08       Impact factor: 3.464

2.  Popliteal artery stenting using flexible tantalum stents.

Authors:  E P Strecker; I B Boos; D Göttmann; S Vetter; W Haase
Journal:  Cardiovasc Intervent Radiol       Date:  2001 May-Jun       Impact factor: 2.740

3.  Kissing stents in the aortic bifurcation.

Authors:  F O Mendelsohn; R M Santos; J J Crowley; R J Lederman; F R Cobb; H R Phillips; N J Weissman; R S Stack
Journal:  Am Heart J       Date:  1998-10       Impact factor: 4.749

Review 4.  Lower-extremity arteriosclerosis as a reflection of a systemic process: implications for concomitant coronary and carotid disease.

Authors:  J Dormandy; L Heeck; S Vig
Journal:  Semin Vasc Surg       Date:  1999-06       Impact factor: 1.000

5.  PTA versus carbofilm-coated stents in infrapopliteal arteries: pilot study.

Authors:  T Rand; A Basile; M Cejna; D Fleischmann; M Funovics; M Gschwendtner; M Haumer; I Von Katzler; J Kettenbach; F Lomoschitz; C Luft; E Minar; B Schneider; M Schoder; J Lammer
Journal:  Cardiovasc Intervent Radiol       Date:  2006 Jan-Feb       Impact factor: 2.740

6.  [Intraluminal Palmaz stent implantation. The first clinical case report on a balloon-expanded vascular prosthesis].

Authors:  J C Palmaz; G M Richter; G Nöldge; G W Kauffmann; W Wenz
Journal:  Radiologe       Date:  1987-12       Impact factor: 0.635

7.  Percutaneous arterial grafting.

Authors:  A H Cragg; G Lund; J A Rysavy; E Salomonowitz; W R Castaneda-Zuniga; K Amplatz
Journal:  Radiology       Date:  1984-01       Impact factor: 11.105

8.  Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery.

Authors:  Martin Schillinger; Schila Sabeti; Christian Loewe; Petra Dick; Jasmin Amighi; Wolfgang Mlekusch; Oliver Schlager; Manfred Cejna; Johannes Lammer; Erich Minar
Journal:  N Engl J Med       Date:  2006-05-04       Impact factor: 91.245

9.  Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch Iliac Stent Trial Study Group.

Authors:  E Tetteroo; Y van der Graaf; J L Bosch; A D van Engelen; M G Hunink; B C Eikelboom; W P Mali
Journal:  Lancet       Date:  1998-04-18       Impact factor: 79.321

10.  Hemobahn stent-grafts for treatment of femoropopliteal arterial obstructions: midterm results of a prospective trial.

Authors:  Thomas Jahnke; Reimer Andresen; Stefan Müller-Hülsbeck; Fritz K W Schäfer; Götz Voshage; Martin Heller; Joachim Brossmann
Journal:  J Vasc Interv Radiol       Date:  2003-01       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.